When does Herceptin Hylecta lose exclusivity?
Herceptin Hylecta (trastuzumab + hyaluronidase-zzxf) has a patent/exclusivity timeline that depends on the specific jurisdiction and the type of exclusivity being referenced (for example, U.S. patent expiration versus FDA exclusivity like NCE or 3-year/7-year exclusivities, or any additional patent listed in the Orange Book). The provided information does not include any specific “loss of exclusivity” date for Herceptin Hylecta, so I can’t state an accurate date from your prompt alone.
If you tell me the country (most commonly the U.S., EU/UK, or Canada) and whether you mean “patent expiration” or “regulatory exclusivity,” I can narrow to the correct loss-of-exclusivity date.
What counts as “loss of exclusivity” for a drug like Herceptin Hylecta?
Search results for “loss of exclusivity date” usually refer to one of these:
- The last patent expiration (often derived from Orange Book listings in the U.S.).
- FDA regulatory exclusivity (which can be different from patents).
- Sometimes “commercial exclusivity” used by pricing/market-access sources, which may reflect launch timing or payor contracting, not strictly legal exclusivity.
Different definitions produce different dates, so the exact meaning matters.
Which details do you need to look up the exact date?
To pin down the right date, you typically need at least:
- Jurisdiction (e.g., U.S. vs EU vs UK vs Canada)
- Product identifier (brand name can map to multiple listings)
- Whether you want “first generic/biosimilar launch eligibility,” which is often tied to the last blocking patent, not the earliest.
Quick next step
Reply with:
1) Region: U.S., EU/UK, or Canada (or another country)
2) Definition: patent expiration or regulatory exclusivity
3) If you have it, the source you’re using (e.g., an Orange Book ID, a specific listing link, or a screenshot)
…and I’ll give you the exact loss-of-exclusivity date tied to that definition.